

## CDK 4/6 dosing study supports DiviTum®TKa as an early and effective tool in treatment monitoring and prediction of response

**Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world's leading breast cancer conference, SABCs. The study supports using DiviTum®TKa to monitor efficacy during treatment and predict response to the CDK 4/6 inhibitor palbociclib.**

“The results from our study support using DiviTum®TKa to monitor efficacy during treatment and predict response to palbociclib, a standard therapy for women with metastatic breast cancer. It is interesting to learn that DiviTum®TKa can identify progression many months ahead of imaging,” said Jairam Krishnamurthy, Lead Author of the study at Division of Oncology/Hematology, University of Nebraska Medical Center.

The current study examines the capability of DiviTum®TKa to be an early predictor of treatment efficacy, and also as a tool for serial monitoring of women with metastatic breast cancer. The study tests a new dosing schedule of a CDK 4/6 inhibitor (palbociclib) and uses DiviTum®TKa to predict response of the therapy. Serum samples were collected pre-treatment and during therapy from 51 patients.

Results show that patients with a tumor response or no disease progression as their best response had significantly lower DiviTum®TKa values at baseline than patients with progressive disease as their best response. During serial monitoring a rise in thymidine kinase activity (TKa) was a predictor of disease progression more than three months prior to imaging progression. The study investigators conclude that serum TKa levels at baseline and on-therapy dynamics show promise for response prediction and monitoring of palbociclib therapy.

“One of our original hypotheses with the DiviTum®TKa test was that TKa levels would be a strong predictor of the treatment effect of cell cycle regulating therapies. In examining the relationship between TKa and treatment with a CDK 4/6 inhibitor, we see strong clinical data that supports that hypothesis. We are very appreciative of the work done by the investigators and their patients to further advance the science.” said Anders Rylander, CEO of Biovica.

### Contact

---

Anders Rylander, CEO

Phone: +46-18-444 48 35

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

### Biovica – Treatment decisions with greater confidence

---

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, [info@fnca.se](mailto:info@fnca.se), +46 8 528 00 399. For more information please visit: [www.biovica.com](http://www.biovica.com).

**Attachments**

---

[CDK 4/6 dosing study supports DiviTum®TKa as an early and effective tool in treatment monitoring and prediction of response](#)